Komori
Statutory disclosure document4889Renascience Inc.Pharmaceuticals

Confirmation of Reporting on the Transfer of Shares Issued through a Third-Party Allotment (New Shares)

CVI Investments, Inc. entered into an undertaking regarding the new shares it will acquire from Renascience Inc. through a third-party allotment, agreeing to report any transfer made within 2 years after acquisition, confirm its ownership status, and consent to submission to the Tokyo Stock Exchange and public inspection.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
263400
Shares
Wording
Definitive
How definitive the wording is.

Decision and Details

Confirmation of Reporting on the Transfer of Shares Issued through a Third-Party Allotment (New Shares)

Decision26 March 2026 (date of undertaking)
Period Covered2 years from 26 March 2026
ImplementationScheduled allotment on 26 March 2026 (scheduled)
Going forwardIf Party A transfers the shares in question, Party A will immediately report the transfer to Party B, and Party B will report the details to the Tokyo Stock Exchange in writing. Party B will submit a copy of this undertaking to the Tokyo Stock Exchange immediately after the undertaking is executed.
AmountTransfer price (to be reported if a transfer occurs)
Quantity / scale263,400 shares of Party B
Reason

Based on Article 422 of the Tokyo Stock Exchange Listing Regulations and Part II, Chapter 4, Section 2, Subsection 2 of the Enforcement Rules

Decision and Details
ItemDetails
Matter CoveredConfirmation of Reporting on the Transfer of Shares Issued through a Third-Party Allotment (New Shares)
Decision Date26 March 2026 (date of undertaking)
Implementation DateScheduled allotment on 26 March 2026 (scheduled)
Period Covered2 years from 26 March 2026
AmountTransfer price (to be reported if a transfer occurs)
Quantity / scale263,400 shares of Party B
ReasonBased on Article 422 of the Tokyo Stock Exchange Listing Regulations and Part II, Chapter 4, Section 2, Subsection 2 of the Enforcement Rules
Governing RuleArticle 422 of the TSE Listing Regulations and Part II, Chapter 4, Section 2, Subsection 2 of the Enforcement Rules
Future plansIf Party A transfers the shares in question, Party A will immediately report the transfer to Party B, and Party B will report the details to the Tokyo Stock Exchange in writing. Party B will submit a copy of this undertaking to the Tokyo Stock Exchange immediately after the undertaking is executed.
Items this document does not state (3)
Decision-Making BodyImpact on Business PerformanceRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Pursuant to Article 422 of the Tokyo Stock Exchange Listing Regulations and Part II, Chapter 4, Section 2, Subsection 2 of the Enforcement Rules.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Confirmation of Reporting on the Transfer of Shares Issued through a Third-Party Allotment (New Shares) | Renascience Inc. (4889) timely disclosure | Komori